Current oncology最新文献

{"title":"Comparison of CT-Guided Microwave Ablation of Liver Malignancies with and Without Intra-Arterial Catheter Placement for Contrast Administration.","authors":"Anne Bettina Beeskow, Holger Gößmann, Hans-Jonas Meyer, Daniel Seehofer, Thomas Berg, Florian van Bömmel, Aaron Schindler, Manuel Florian Struck, Timm Denecke, Sebastian Ebel","doi":"10.3390/curroncol32010028","DOIUrl":"10.3390/curroncol32010028","url":null,"abstract":"<p><strong>Background: </strong>The aim of this study was to compare microwave ablation (MWA) with and without prior placement of an intra-arterial catheter for the purpose of application of contrast medium (CM).</p><p><strong>Methods: </strong>148 patients (45 female, 65.1 ± 14.9 years) with liver tumors who underwent CT-guided MWA were included. Of these, 25 patients had an IA catheter placed in the hepatic artery.</p><p><strong>Results: </strong>37 patients underwent planning imaging for MWA without CM. A total of 86 patients received a standard dose of 80 mL intravenous (IV) CM for the planning scans. The patients with an IA catheter (<i>n</i> = 25) received an IA application of 10 mL CM. A total of 29 patients received contrast-enhanced scans in the PV phase for control of needle positioning after IV application of a standard dose of 80 mL CM. In patients with an IA catheter, control of the needle position was performed by single-slice scans. IA CM application during the ablation enabled monitoring of the ablation zone. Over the entire intervention, patients with IA catheters received less CM as compared to patients without an IA catheter (39.1 ± 10.4 mL vs. 141 ± 39.69 mL; <i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>IA catheter placement was associated with a significant decrease of the amount of CM during MWA and enabled monitoring of the ablation zone.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11764381/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143032376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting High-Grade Acute Urinary Toxicity and Lower Gastrointestinal Toxicity After Postoperative Volumetric Modulated Arc Therapy for Cervical and Endometrial Cancer Using a Normal Tissue Complication Probability Model.","authors":"Tianyu Yang, Zhe Ji, Runhong Lei, Ang Qu, Weijuan Jiang, Xiuwen Deng, Ping Jiang","doi":"10.3390/curroncol32010026","DOIUrl":"10.3390/curroncol32010026","url":null,"abstract":"<p><p>(1) Background: Volumetric modulated arc therapy (VMAT) can deliver more accurate dose distribution and reduce radiotherapy-induced toxicities for postoperative cervical and endometrial cancer. This study aims to retrospectively analyze the relationship between dosimetric parameters of organs at risk (OARs) and acute toxicities and provide suggestions for the dose constraints. (2) Methods: A total of 164 postoperative cervical and endometrial cancer patients were retrospectively analyzed, and the endpoints were grade ≥ 2 acute urinary toxicity (AUT) and acute lower gastrointestinal toxicity (ALGIT). The normal tissue complication probability (NTCP) model was established using the logistic regression model. Restricted cubic spline (RCS) curves were used to explore the association between dosimetric parameters and toxicities. The receiver operating characteristic (ROC) curve, calibration curve, Akaike's corrected information criterion (AICc), decision curve analysis (DCA), and clinical impact curve (CIC) were analyzed to evaluate the performance of NTCP models. (3) Results: Bladder V_40Gy was identified to develop the NTCP model of AUT, and the mean AUC was 0.69 (CI: 0.58-0.80). Three candidate predictors, namely the small intestine V_30Gy, colon D_45%, and rectum D_55%, were identified to develop the NTCP model of ALGIT, and the mean AUC was 0.71 (CI: 0.61-0.80). Both models were considered to have relatively good discriminative accuracy and could provide a high net benefit in clinical applications. (4) Conclusions: We developed NTCP models to predict the probability for grade ≥ 2 AUT and ALGIT. We recommend that bladder V_40Gy, the small intestine V_30Gy, colon D_45%, and rectum D_55% be controlled below 42%, 20.4%, 16.9 Gy, and 32.0 Gy, respectively.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11763444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143032506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility and Preliminary Effects of Acupuncture for Cognitive Dysfunction in Diverse Cancer Survivors: A Pilot, Randomized, Placebo-Controlled Trial.","authors":"Xiaotong Li, Kaitlin Lampson, Tim A Ahles, James C Root, Q Susan Li, Yuelin Li, Anam Ahsan, Jun J Mao, Kevin T Liou","doi":"10.3390/curroncol32010027","DOIUrl":"10.3390/curroncol32010027","url":null,"abstract":"<p><p>(1) Background: This pilot study evaluates the feasibility and preliminary effects of acupuncture for cancer-related cognitive dysfunction (CRCD) in cancer survivors. (2) Methods: A randomized trial comparing real acupuncture (RA) to sham acupuncture (SA) and waitlist control (WLC) among cancer survivors reporting cognitive difficulties. Interventions were delivered weekly over 10 weeks. Feasibility was evaluated by recruitment, treatment adherence, and assessment completion. Subjective CRCD was assessed by the Functional Assessment of Cancer Therapy-Cognitive Function-Perceived Cognitive Impairment subscale (FACT-Cog PCI) and objective CRCD was assessed by the Hopkins Verbal Learning Test-Revised (HVLT-R). (3) Results: 32 participants (57.1% of eligible patients) were enrolled. All participants in acupuncture groups completed ≥8 of 10 treatments. Assessment completion rate was 100% for all participants. From baseline to week 10, the RA group (n = 19) reported a clinically meaningful 17.3-point increase in FACT-Cog PCI (95% confidence interval [CI] 12.5 to 22.1), compared to 9.7 points (95% CI 2.8 to 16.7) in the SA group (n = 9), and 6.8 points (95% CI -3.7 to 17.2) in the WLC group (n = 4). In the subgroup analysis among patients with a below-average baseline HVLT-R (T-score < 50), the RA group (n = 8) increased FACT-Cog PCI scores by 20.4 (95% CI 13.6 to 27.3), compared to 11.1 points (95% CI 0.6 to 21.5) in the SA group (n = 5). The improvements from RA persisted through week 16 in both the total sample and the sub-group. Eleven mild adverse events were reported, with pain and bleeding at the needling sites being the most common. (4) Conclusions: The findings support the feasibility and safety of conducting a randomized, placebo-controlled trial to evaluate acupuncture for cognitive dysfunction in cancer survivors.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11763785/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143032388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Necrosis in Preoperative Cross-Sectional Imaging and Postoperative Histology Is a Diagnostic Marker for Malignancy of Adrenocortical Tumors.","authors":"Agata Dukaczewska, Stephan R Marticorena Garcia, Simon Ponsel, Alexandra Webster, Frederike Butz, Eva M Dobrindt, Johann Pratschke, David Horst, Martina T Mogl, Catarina A Kunze","doi":"10.3390/curroncol32010025","DOIUrl":"10.3390/curroncol32010025","url":null,"abstract":"<p><p>Necrosis in postoperative histology has been reported as being specific for adrenocortical carcinoma (ACC) compared to adenoma. We therefore retrospectively analyzed the diagnostic accuracy of the finding of necrosis in preoperative cross-sectional imaging and postoperative histology as a marker for ACC in our patient cohort. Among the 411 adrenalectomies in 396 patients performed between 2008 and April 2022, 30 cases of ACC (7.6%) were identified, with one tumor measuring less than 40 mm excluded. All 45 benign adrenocortical tumors of at least 40 mm in diameter, including Cushing, Conn, and hormonally inactive adenomas, served as controls. Preoperative imaging was available for 40 benign and 27 malignant adrenocortical tumors. In total, 10 of 40 (25%) benign adrenocortical tumors and 22 of 27 (81%) ACCs showed signs of possible necrosis in preoperative imaging. Pathologic examination confirmed necrosis in 1 of 40 (2.5%) benign tumors and in 26 out of 27 (96%) malignant tumors. The specificities of possible necrosis in preoperative imaging and necrosis in histology for diagnosing ACC were 75% and 97.5%, respectively, whereas the sensitivities were 81% and 96%, respectively. Signs of possible necrosis in radiologic imaging and tumor necrosis in histology proved to be very good predictive markers for the diagnosis of malignant adrenocortical tumors.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11764034/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143032504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Financial Toxicity Experience of Patients with Colorectal Cancer During Chemotherapy: A Qualitative Study.","authors":"Yanli Yao, Shijing Zhang, Qun Yu, Xia Zhao, Xinqiong Zhang","doi":"10.3390/curroncol32010023","DOIUrl":"10.3390/curroncol32010023","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to explore the experience of financial toxicity in patients with colorectal cancer during chemotherapy and to inform the development of targeted interventions.</p><p><strong>Methods: </strong>A descriptive qualitative research method was used to conduct semi-structured interviews with a purposive sample of 15 patients with colorectal cancer undergoing chemotherapy who attended the Department of Medical Oncology of the First Affiliated Hospital of Anhui Medical University from March to June 2024, and the data were organized and analyzed using the Nvivo 11.0 qualitative data analysis software and the thematic analysis method.</p><p><strong>Results: </strong>Four themes were extracted: patients with chemotherapy-stage colorectal cancer bear direct and indirect multifaceted economic pressures, are affected by multidimensional risk factors, which cause multiple adverse outcomes, and cope with financial toxicity in various ways.</p><p><strong>Conclusions: </strong>The experience of financial toxicity in colorectal cancer patients undergoing chemotherapy is presented in a multidimensional format, with multiple causes influencing their financial toxicity. In the future, healthcare professionals should identify patients at high risk for financial toxicity, provide financial toxicity interventions and support, and mitigate their exposure to financial toxicity.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11764152/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143031638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Age, Comorbidity, and Frailty in the Prediction of Postoperative Complications After Surgery for Vulvar Cancer: A Retrospective Cohort Study with the Development of a Nomogram.","authors":"Giovanni Delli Carpini, Francesco Sopracordevole, Camilla Cicoli, Marco Bernardi, Lucia Giuliani, Mariasole Fichera, Nicolò Clemente, Anna Del Fabro, Jacopo Di Giuseppe, Luca Giannella, Enrico Busato, Andrea Ciavattini","doi":"10.3390/curroncol32010021","DOIUrl":"10.3390/curroncol32010021","url":null,"abstract":"<p><p>Surgery is the cornerstone of vulvar cancer treatment, but it is associated with a significant risk of complications that may impact prognosis, particularly in older patients with multiple comorbidities. The objective of this study was to evaluate the role of age, comorbidities, and frailty in predicting postoperative complications after vulvar cancer surgery and to develop a predictive nomogram. A retrospective cohort study was conducted, including patients who underwent surgery for vulvar cancer at two Italian institutions from January 2018 to December 2023. A logistic regression model for the rate of Clavien-Dindo 2+ 30-days complications was run, considering the age-adjusted Charlson Comorbidity Index (AACCI), body mass index (BMI), and frailty as exposures. Lesion characteristics and surgical procedures were considered as confounders. Among the 225 included patients, 50 (22.2%) had a grade 2+ complication. The predictive score of the nomogram ranged from 44 to 140. The AACCI (0-64 points) and BMI (0-100 points) were independently associated with a risk of complications. A nomogram including the AACCI and BMI predicts the risk of complications for patients undergoing surgery for vulvar cancer. The preoperative determination of the risk of complications enables surgical planning and allows a tailored peri- and postoperative management plan.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11763996/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143031635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Immune Landscape and Its Potential for Immunotherapy in Advanced Biliary Tract Cancer.","authors":"Andry Santoso, Iris Levink, Rille Pihlak, Ian Chau","doi":"10.3390/curroncol32010024","DOIUrl":"10.3390/curroncol32010024","url":null,"abstract":"<p><p>Biliary tract cancers (BTC) are a highly heterogeneous group of cancers at the genomic, epigenetic and molecular levels. The vast majority of patients initially present at an advanced (unresectable) disease stage due to a lack of symptoms and an aggressive tumour biology. Chemotherapy has been the mainstay of treatment in patients with advanced BTC but the survival outcomes and prognosis remain poor. The addition of immune checkpoint inhibitors (ICI) to chemotherapy have shown only a marginal benefit over chemotherapy alone due to the complex tumour immune microenvironment of these cancers. This review appraises our current understanding of the immune landscape of advanced BTC, including emerging transcriptome-based classifications, highlighting the mechanisms of immune evasion and resistance to ICI and their therapeutic implications. It describes the shifting treatment paradigm from traditional chemotherapy to immunotherapy combinations as well as the potential biomarkers for predicting response to ICI.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11763487/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143031640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pain and Frailty in Childhood Cancer Survivors: A Narrative Review.","authors":"Chiara Papini, Jaspreet K Sodhi, Cassie M Argenbright, Kirsten K Ness, Tara M Brinkman","doi":"10.3390/curroncol32010022","DOIUrl":"10.3390/curroncol32010022","url":null,"abstract":"<p><p>A significant proportion of childhood cancer survivors experience persistent health problems related to cancer or cancer treatment exposures, including accelerated or early onset of aging. Survivors are more likely than non-cancer peers to present a frail phenotype suggestive of reduced physiologic reserve and have symptoms that interfere with function in daily life, including pain. Studies in the general population, mostly among older adults, suggest that pain is a significant contributor to development and progression of frail health. This association has not been explored among childhood cancer survivors. In this narrative review, we highlight this gap by summarizing the epidemiologic evidence on pain and frailty, including their prevalence, common risk factors, and correlates in childhood cancer survivors. We further discuss associations between pain and frailty in non-cancer populations, likely biological mechanisms in survivors, and potential interventions targeting both domains.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11763768/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143032565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementation of a Hepatitis B Screening Program in Patients Receiving Systemic Anti-Cancer Therapy.","authors":"Jennifer Leigh, Ranjeeta Mallick, Stephanie Brule, Lisa Rambout, Jennifer Newton, Dominick Bossé, Curtis Cooper, Joanna Gotfrit","doi":"10.3390/curroncol32010020","DOIUrl":"10.3390/curroncol32010020","url":null,"abstract":"<p><p>Cancer patients receiving non-endocrine therapies are at risk of hepatitis B virus (HBV) reactivation (HBVr). Guidelines recommend HBV screening prior to treatment. The Ottawa Hospital Cancer Center implemented a screening pilot for all patients receiving FOLFOX-based regimens between January and April 2023. We assessed the pilot from a quality improvement perspective. Charts were retrospectively reviewed, and patient and disease characteristics were collected. The primary endpoint was to identify the proportion of patients who underwent HBV screening prior to treatment start. Univariate analyses assessed the association between baseline characteristics and failure to screen. Quality metrics were also reviewed. There were 32/42 patients (76.2%) who completed screening, and 5 (11.9%) had a positive screen. The majority of eligible patients (59.5%) completed screening prior to the first treatment as intended. Four of five patients who tested positive were referred to Infectious Diseases. Of those, one received antivirals for chronic HBV. There were no treatment delays due to pending screening and no HBV reactivation. Receipt of prior systemic therapy was significantly associated with failure to screen (55 vs. 95%, OR 17.1 (95% CI 1.92-153), <i>p</i> = 0.011). The results of this pilot highlight the importance of building HBV screening into standardized treatment plans and engaging all team members to ensure high levels of screening. Prior systemic therapy receipt was associated with failure to screen, and thus, programs should include education on the necessity of screening as recommended by medical guidelines.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11764458/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143032556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective, Non-Interventional, Multicenter Study on the Effectiveness and Safety of Intravesical Bacillus Calmette-Guerin in Patients with Non-Muscle-Invasive Bladder Cancer: Real-World Experience from Six Hospital Centers in Greece.","authors":"Panagiotis Angelopoulos, Titos Markopoulos, Lazaros Lazarou, Andreas Skolarikos, Panagiotis Stamatakos, Georgios I Papadopoulos, Charalampos Fragkoulis, Konstantinos Ntoumas, Napoleon Moulavasilis, Panagiotis Levis, Dimitrios Papanikolaou, Ioannis Sokolakis, Konstantinos Hatzimouratidis, Charalampos Tzanetakos, Marina Psarra, George Mavridoglou, Konstantinos Skriapas, Dimitra Akrivou, Dimitrios Karagiannis, Christos Noutsos, Andreas Georgiou, Konstantinos Hastazeris, George Gourzoulidis, Dionysios Mitropoulos","doi":"10.3390/curroncol32010018","DOIUrl":"10.3390/curroncol32010018","url":null,"abstract":"<p><strong>Background: </strong>While the clinical application of SII-ONCO-Bacillus Calmette-Guerin (BCG) for non-muscle-invasive bladder cancer (NMIBC) is well established in Greece, there is a lack of real-world data on its effectiveness and safety. This retrospective, observational, multicenter, chart-review study aims to provide real-life data on the effectiveness and safety of SII-ONCO-BCG in patients with intermediate- and high-risk NMIBC.</p><p><strong>Methods: </strong>From January 2016 to December 2023, medical records from six hospital centers were reviewed for adult patients with histologically confirmed stage Ta or T1 NMIBC (with or without carcinoma in situ [CIS]) who received at least one maintenance course of SII-ONCO-BCG after induction. Tumor recurrence and progression were monitored at scheduled time intervals. Primary outcomes included recurrence-free survival (RFS) and progression-free survival (PFS), while adverse events (AEs) constituted secondary outcomes.</p><p><strong>Results: </strong>A total of 162 patients receiving SII-ONCO-BCG were enrolled. Among all patients, 145 (89.5%) patients were men, 88 (54.3%) aged 70 years or older, 103 (63.6%) had T1, 43 (26.5%) Ta, and 21 (12.9%) concurrent CIS. The median follow-up duration was 28.9 months (range, 5-36) and the mean BCG intravesical instillation courses were 13.7 (range, 9-27). After 3-, 2-, and 1-year follow-up, RFS rates of 85.2% (95% CI, 79.7-90.7%), 85.8% (80.4-91.2%), and 87.0% (81.8-92.3%) were observed, respectively. The corresponding 3-, 2-, and 1-year PFS rates were 96.9% (94.2-99.6%), 96.9% (94.2-99.6%), and 97.5% (95.1-99.9%), respectively. During the whole follow-up period, 24 (14.8%) patients experienced at least one AE.</p><p><strong>Conclusions: </strong>This real-world study demonstrates that SII-ONCO-BCG is an effective and safe treatment for patients with intermediate- and high-risk NMIBC.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11763471/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143031615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}